Takeda Pharmaceutica
4502
End-of-day quote Tokyo - 07/20
4728JPY
-0.13%
Income Statement Evolution
Annual Income Statement Data
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Sales1 770 5311 762 242
EBITDA437 460396 108
Operating profit (EBIT)--
Pre-Tax Profit (EBT)217 205216 350
Net income186 886160 479
EPS ( JPY )239206
Dividend per Share ( JPY )180180
Yield3,47%3,81%
Announcement Date05/14/2018
06:00am
-
Finances - Leverage
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Debt610 494679 746
Finance--
Operating income (EBITDA)437 460396 108
Leverage
(Debt/EBITDA)
1,40x1,72x
Capital Expenditure67 00582 521
Book Value Per Share (BVPS)2 557  JPY2 569  JPY
Cash Flow per Share490  JPY435  JPY
Announcement Date05/14/2018
06:00am
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 3 762 074 M JPY -
Entreprise Value (EV) 4 441 820 M JPY 4 302 842 M JPY
Valuation 2019e 2020e
P/E ratio (Price / EPS) 23,0x 20,3x
Capitalization / Revenue 2,13x 2,06x
EV / Revenue 2,52x 2,36x
EV / EBITDA 11,2x 10,2x
Yield (DPS / Price) 3,81% 3,81%
Price to book (Price / BVPS) 1,84x 1,80x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) - -
operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) 9,11% 11,2%
ROA (Net Profit / Asset) 4,60% 5,14%
ROE (Net Profit / Equities) 7,50% 8,90%
Rate of Dividend 87,5% 77,3%
Balance Sheet Analysis 2019e 2020e
CAPEX / CA   4,68% 4,13%
Cash Flow / Sales 19,3% 21,1%
Capital Intensity (Assets / Sales) 1,98x 2,18x
Financial Leverage (Net Debt / EBITDA) 1,72x 1,29x
Price Earning Ratio
BNA & Dividende